+ Carlton Hoyt, Author at etiraRx Carlton Hoyt, Author at etiraRx Scientific News Media Demonstrates an Affinity for ERX-41

Scientific News Media Demonstrates an Affinity for ERX-41

Following the publication of the article “Targeting LIPA independent of its lipase activity is a therapeutic strategy in solid tumors via induction of endoplasmic reticulum stress” in Nature Cancer, from the lab of etiraRx co-founder Ganesh Raj, scientific news media was quick to pick up on this major breakthrough in cancer research. In the paper, ERX-41 demonstrates “a large therapeutic window, with no adverse effects either on normal mammary epithelial cells or in mice,” potentially providing a route to treating previously untreatable solid cancers, such as triple-negative breast cancer.

A selection of the news articles which have picked up on the story are below.

EurekAlert!: Promising compound kills range of hard-to-treat cancers by targeting a previously undiscovered vulnerability
Yahoo!: EtiraRx’s Licensed ERX-41 Identified as a Potential New Oral Therapy for Multiple Cancers, Company Prepares for Clinical Trials
KAIT-TV: EtiraRx’s Licensed ERX-41 Identified as a Potential New Oral Therapy for Multiple Cancers, Company Prepares for Clinical Trials
News-medical.net: New compound shows promise to kill a range of hard-to-treat cancer types
News-medical.net: New molecule kills a broad spectrum of hard-to-treat cancers
Good News Network: Protein Destroys ‘Hard to Treat’ Cancers, Could Become ‘One Size Fits All’ Pill
Interesting Engineering: Scientists discovered a new molecule that kills even the deadliest cancer
MedicalXpress: Promising compound kills range of hard-to-treat cancers by targeting a previously undiscovered vulnerability
Bioengineer.org: Promising compound kills range of hard-to-treat cancers by targeting a previously undiscovered vulnerability
Mirage News: Promising compound kills range of hard-to-treat cancers by targeting previously undiscovered vulnerability
ScienMag: Promising compound kills range of hard-to-treat cancers by targeting a previously undiscovered vulnerability
Ticker Tech: EtiraRx’s Licensed ERX-41 Identified as a Potential New Oral Therapy for Multiple Cancers, Company Prepares for Clinical Trials